Target Information
Target General Infomation | |||||
---|---|---|---|---|---|
Target ID |
T32247
|
||||
Former ID |
TTDS00485
|
||||
Target Name |
Calcitonin receptor
|
||||
Gene Name |
CALCR
|
||||
Synonyms |
CT-R; CALCR
|
||||
Target Type |
Successful
|
||||
Disease | Hypertension [ICD9: 401; ICD10: I10-I16] | ||||
Osteoporosis [ICD9: 733.0, V07.4; ICD10: M80-M81, Z79.890] | |||||
Pain; Postmenopausal osteoporosis [ICD9:338, 356.0, 356.8, 780, 733; ICD10: G64, G90.0, R52, G89, M80-M81] | |||||
Paget's disease [ICD9: 731; ICD10: M88] | |||||
Function |
Thisis a receptor for calcitonin. The activity of this receptor is mediated by G proteins which activate adenylyl cyclase. The calcitonin receptor is thought to couple to the heterotrimeric guanosine triphosphate-binding protein that is sensitive to cholera toxin.
|
||||
BioChemical Class |
GPCR secretin
|
||||
Target Validation |
T32247
|
||||
UniProt ID | |||||
Sequence |
MQFSGEKISGQRDLQKSKMRFTFTSRCLALFLLLNHPTPILPAFSNQTYPTIEPKPFLYV
VGRKKMMDAQYKCYDRMQQLPAYQGEGPYCNRTWDGWLCWDDTPAGVLSYQFCPDYFPDF DPSEKVTKYCDEKGVWFKHPENNRTWSNYTMCNAFTPEKLKNAYVLYYLAIVGHSLSIFT LVISLGIFVFFRKLTTIFPLNWKYRKALSLGCQRVTLHKNMFLTYILNSMIIIIHLVEVV PNGELVRRDPVSCKILHFFHQYMMACNYFWMLCEGIYLHTLIVVAVFTEKQRLRWYYLLG WGFPLVPTTIHAITRAVYFNDNCWLSVETHLLYIIHGPVMAALVVNFFFLLNIVRVLVTK MRETHEAESHMYLKAVKATMILVPLLGIQFVVFPWRPSNKMLGKIYDYVMHSLIHFQGFF VATIYCFCNNEVQTTVKRQWAQFKIQWNQRWGRRPSNRSARAAAAAAEAGDIPIYICHQE PRNEPANNQGEESAEIIPLNIIEQESSA |
||||
Drugs and Mode of Action | |||||
Modulator | Calcitonin Human | Drug Info | [556264] | ||
Calcitonin oral | Drug Info | [544165] | |||
TJN-220 | Drug Info | [533777] | |||
Inhibitor | CGNLSTCBLGTYTQDFNKFHZYPQTAIGVGAP-amide | Drug Info | [526273] | ||
CGNLSTCBLGTYTQDF[DKFHO]YPQTAIGVGAP-amide | Drug Info | [526273] | |||
CGNLSTCMLGTYTQDFc[DKFHK]FPQTAIGVGAP-amide | Drug Info | [526273] | |||
CGNLSTCMLGTYTQDFc[DKFHO]FPQTAIGVGAP-amide | Drug Info | [526273] | |||
CGNLSTCMLGTYTQDFNKFHTFPQTAIGVGAP-amide | Drug Info | [526273] | |||
CGNLSTCMLGTYTQDFNKPHTFPQTAIGVGAP-amide | Drug Info | [526273] | |||
CGNLSTCMLGTYTQDFNPFHTFPQTAIGVGAP-amide | Drug Info | [526273] | |||
CGNLSTCMLGTYTQDFNPKHTFPQTAIGVGAP-amide | Drug Info | [526273] | |||
CSNLSTCVLGKLSQELc[DKLHK]YPRTNTGSGTP-amide | Drug Info | [526273] | |||
CSNLSTCVLGKLSQELc[DKLHO]YPRTNTGSGTP-amide | Drug Info | [526273] | |||
CSNLSTCVLGKLSQELc[DKLQK]YPRTNTGSGTP-amide | Drug Info | [526273] | |||
CSNLSTCVLGKLSQELHKLQTYPRTNTGSGTP-amide | Drug Info | [526273] | |||
CSNLSTCVLGKLSQELNKLHBYPRTNTGSGTP-amide | Drug Info | [526273] | |||
Binder | Salmon Calcitonin | Drug Info | [537494], [537723] | ||
Target Expression Profile (TEP) and Drug Resistance Mutation (DRM) | |||||
TEP | EXP Info | ||||
Pathways | |||||
KEGG Pathway | Neuroactive ligand-receptor interaction | ||||
Osteoclast differentiation | |||||
NetPath Pathway | RANKL Signaling Pathway | ||||
Reactome | G alpha (s) signalling events | ||||
Calcitonin-like ligand receptors | |||||
WikiPathways | GPCRs, Class B Secretin-like | ||||
RANKL/RANK Signaling Pathway | |||||
GPCR ligand binding | |||||
GPCR downstream signaling | |||||
References | |||||
Ref 531853 | A phase 3 trial of the efficacy and safety of oral recombinant calcitonin: the Oral Calcitonin in Postmenopausal Osteoporosis (ORACAL) trial. J Bone Miner Res. 2012 Aug;27(8):1821-9. | ||||
Ref 536361 | Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007 Mar;70(3):461-77. Epub 2007 Feb 20. | ||||
Ref 542004 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6973). | ||||
Ref 526273 | J Med Chem. 2002 Feb 28;45(5):1108-21.Side-chain lactam-bridge conformational constraints differentiate the activities of salmon and human calcitonins and reveal a new design concept for potent calcitonin analogues. | ||||
Ref 533777 | Evaluation of the long-lasting antihypertensive action of 7-O-ethylfangchinoline. Jpn J Pharmacol. 1994 Sep;66(1):35-46. | ||||
Ref 537494 | Improved absorption of salmon calcitonin by ultraflexible liposomes through intranasal delivery. Peptides. 2009 Jul;30(7):1288-95. Epub 2009 Apr 7. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.